

	2016 Rupees	2015 Rupees
<b>10.1 Due from associated companies - considered good</b>		
GlaxoSmithKline Pakistan Limited	77,452,334	-
GlaxoSmithKline Consumer Health Care, Singapore	26,325,000	-
GlaxoSmithKline Limited, Egypt	1,892,550	-
GlaxoSmithKline Export Limited, UK	7,391,530	-
	<u>113,061,414</u>	<u>-</u>

## 11. CASH AND BANK BALANCES

With bank

on deposit account - note 11.1	500,000,000	-
on current account	170,342,359	3,090
	<u>670,342,359</u>	<u>3,090</u>

11.1 At December 31, 2016 the rates of mark-up on term deposit account were 4.4% to 5.5% (2015: Nil) per annum.

## 12. SHARE CAPITAL

Authorised share capital

2016	2015		2016	2015
			Rupees	
<u>100,000,000</u>	<u>10,000</u>	Ordinary shares of Rs. 10 each	<u>1,000,000,000</u>	<u>100,000</u>

Issued, subscribed and paid-up capital

Ordinary shares of Rs. 10 each				
2016	2015			
10,000		3 Shares allotted for consideration paid in cash	100,000	30
95,540,183		- Shares allotted for consideration other than cash under the Scheme - note 1.1	955,401,830	-
<u>95,550,183</u>	<u>3</u>		<u>955,501,830</u>	<u>30</u>

12.1 As at December 31, 2016 Glaxosmithkline Consumer Healthcare B.V. and its nominees held 78,918,934 shares (2015: S.R. One International B.V., Netherlands through its nominees held 3 shares).

	2016 Rupees	2015 Rupees
<b>13. RESERVES</b>		
Capital reserve - note 13.1	101,913,533	-
Unappropriated profit / Accumulated loss	539,161,029	(252,700)
	<u>641,074,562</u>	<u>(252,700)</u>

**13.1** This represents reserve in respect of Scheme of Arrangement as detailed in note 1.1.

#### **14. STAFF RETIREMENT BENEFITS**

##### **14.1 Staff retirement benefit**

**14.1.1** The Company operates an approved funded gratuity scheme for all of its eligible employees. Actuarial valuation of these Plans is carried out every year and the latest actuarial valuation was carried out as of December 31, 2016 using the Projected Unit Credit Method.

**14.1.2** Plan assets held in trust are governed by local regulations which mainly include Trust Act, 1882; the Companies Ordinance, 1984; Income Tax Rules, 2002 and the Rules under the trust deeds. Responsibility for governance of the Plans, including investment decisions and contribution schedules, lies with the Boards of Trustees of relevant Plans. The Company appoints the trustees and all trustees are employees of the Company.

**14.1.3** Details of the Plan as per the actuarial valuation are as follows:

	2016 Rupees	2015 Rupees
<b>14.1.4 Balance sheet reconciliation</b>		
Present value of defined benefit obligation at December 31 - note 14.1.5	54,520,074	-
Fair value of plan assets at December 31 - note 14.1.6	(45,973,630)	-
Deficit	<u>8,546,444</u>	<u>-</u>

##### **14.1.5 Movement in the present value of defined benefit obligation**

Balance transferred from GlaxoSmithKline Pakistan Limited Employees' Gratuity Fund	41,142,000	
Benefits paid by the Plan	(314,512)	-
Current service cost	5,295,420	-
Interest cost	2,200,242	-
Remeasurement on obligation	6,196,924	-
Balance at December 31	<u>54,520,074</u>	<u>-</u>



	2016 Rupees	2015 Rupees
<b>14.1.6 Movement in the fair value of plan assets</b>		
Balance transferred from GlaxoSmithKline Pakistan Limited Employees' Gratuity Fund	41,142,000	
Contributions made to the Plan	5,019,828	-
Benefits paid by the Plan	(314,512)	-
Interest income	2,293,192	-
Remeasurement on plan assets	(2,166,878)	-
Balance at December 31	<u>45,973,630</u>	<u>-</u>
<b>14.1.7 Expense recognised in profit and loss account</b>		
Current service cost	5,295,420	-
Net interest cost income	(92,950)	-
Expense recognised in profit and loss account	<u>5,202,470</u>	<u>-</u>
<b>14.1.8 Remeasurements recognised in Other Comprehensive Income</b>		
Experience loss	6,196,924	-
Remeasurement of fair value of plan assets	2,166,878	-
	<u>8,363,802</u>	<u>-</u>
<b>14.1.9 Net recognised liability</b>		
Expense recognised in profit and loss account	5,202,470	-
Contribution made to the Plan during the year / period	(5,019,828)	-
Remeasurements recognised in other comprehensive income	8,363,802	-
Recognised liability as at December 31	<u>8,546,444</u>	<u>-</u>
<b>14.1.10</b> Plan assets comprise entirely of cash at bank balances.		

*mm*

	2016	2015
	%	%
<b>14.1.11 Actuarial Assumptions</b>		
Discount rate at December 31	8	N/A
Future salary increases	8	N/A
<b>14.1.12</b> Pre-Retirement mortality was assumed to be SLIC (2001-05) rated down one year and Post-Retirement mortality was assumed to be SLIC (2001-05), but rated down one year. Wives were assumed to be 5 years younger than the husbands.		
<b>14.1.13</b> In case of the funded plans, investment positions are managed within an asset-liability matching (ALM) framework that has been developed to achieve long-term investments that are in line with the obligations under the retirement benefit plan. Within this framework, the ALM objective is to match assets to the retirement benefit obligations by investing in long-term fixed interest securities with maturities that match the benefit payments as they fall due. The Company however is still in the process of devising an investment strategy, and all its plan assets are currently in the form of bank deposits.		

The Company's contribution to gratuity plan in 2017 is expected to amount to Rs. 9.11 million.

## 14.2 Sensitivity analysis for actuarial assumptions

The sensitivity of the defined benefit obligation to changes in the weighted principal assumptions is:

	Change in assumption	Impact on defined benefit obligation	
		Increase in assumption	Decrease in assumption
Discount rate at December 31	1%	(4,354,216)	2,684,137
Future salary increases	1%	2,767,775	(4,488,154)

If longevity increases by 1 year, the resultant increase in obligation is insignificant.

The above sensitivity analyses are based on a change in an assumption while holding all other assumptions constant. In practice, this is unlikely to occur, and changes in some of the assumptions may be correlated. When calculating the sensitivity of the defined benefit obligation to significant actuarial assumptions the same method (present value of the defined benefit obligation calculated with the projected unit credit method at the end of the reporting period) has been applied as when calculating the gratuity liability recognised within the balance sheet.



	2016 Rupees	2015 Rupees			
<b>14.3 Historical information</b>					
<b>Gratuity plan</b>					
Present value of defined benefit obligation	54,520,074	-			
Fair value of plan assets	(45,973,630)	-			
Deficit in the plan	<u>8,546,444</u>	<u>-</u>			
<b>Experience Adjustments</b>					
Loss on obligation (as percentage of plan obligation)	11.37%	-			
Loss on plan assets (as percentage of plan assets)	4.71%	-			
<b>14.4</b> Company's contributions towards the provident fund for the year ended December 31, 2016 amounted to Rs. 4.7 million (2015: Rs. Nil).					
<b>14.5</b> The weighted average duration of approved funded gratuity schemes for its permanent employees is 8.7 years.					
<b>14.6</b> Expected maturity analysis of undiscounted retirement benefit plans.					
At December 31, 2016	Less than a year	Between 1 - 2 years	Between 2 - 5 years	Between 5 - 10 years	Total
	← Rupees →				
Retirement benefit plans	1,476,967	27,162,832	15,530,558	20,502,997	64,673,354
<b>14.7</b> Figures in this note are based on the latest actuarial valuation carried out as at December 31, 2016.					
	2016 Rupees	2015 Rupees			
<b>15. TRADE AND OTHER PAYABLES</b>					
Creditors					
- Associated companies	187,220,876	-			
- Others	80,732,463	-			
Accrued liabilities - note 15.1	852,650,264	252,700			
Advances from customers	58,062,750	-			
Taxes deducted at source and payable to statutory authorities	18,197,711	-			
Workers' Profits Participation Fund	18,683,000	-			
Workers' Welfare Fund	46,473,000	-			
Others	2,996,610	3,060			
	<u>1,265,016,674</u>	<u>255,760</u>			
<b>15.1</b> This includes liability for share based compensation amounting to Rs. 10.48 million (2015: Rs. Nil).					

**16. COMMITMENTS****16.1 Commitments**

Commitments for capital expenditure outstanding as at December 31, 2016 amount to Rs. 32.33 million (2015: Rs. Nil).

	<b>2016 Rupees</b>	For the period from March 31, 2015 to December 31, 2015 Rupees
<b>17. NET SALES</b>		
<b>Manufactured goods</b>		
Gross sales	5,941,497,093	-
Less:		
Commissions, returns and discounts	(231,555,769)	-
Sales tax	(334,136,722)	-
	(565,692,491)	-
	<u>5,375,804,602</u>	<u>-</u>

**17.1** During the year ended December 31, 2015, the Drug Regulatory Authority of Pakistan (DRAP) issued the Drug Pricing Policy 2015 (the Policy) vide a notification dated March 5, 2015. Under the Policy, pending hardship cases were to be decided within period of nine months from the date of notification of the Policy. Prior to the promulgation of the Policy, GSK Pakistan had submitted applications for hardship price increase in respect of certain products which also included Over the Counter (OTC) drugs transferred to the Company from GSK Pakistan under the Scheme of Arrangement.

Due to inaction on the part of DRAP, pending hardship cases remained undecided by DRAP despite lapse of stipulated period of nine months and GSK Pakistan approached the High Court of Sindh ('SHC') in order to avail the long pending hardship price increase. The SHC granted an interim order and restrained DRAP from taking any coercive action.

In December 2016, the SHC passed a Judgement in respect of the hardship cases. Two weeks after the Judgement, DRAP also issued a letter directing GSK Pakistan (on behalf of the Company - see note 1.2) to recall from the market all products on which the hardship price increase is availed, within 7 days of the letter. An Appeal against the aforementioned Judgement was filed before Divisional Bench of SHC. The SHC has directed DRAP not to take any coercive action.

The management of the Company believes that there are strong grounds of Appeal to support the stance of the Company on hardship price increases.

	2016 Rupees	For the period from March 31, 2015 to December 31, 2015 Rupees
<b>18. COST OF SALES</b>		
Raw and packing materials consumed	368,828,939	-
Manufacturing charges to third parties	123,802,506	-
Salaries, wages and other benefits - note 18.1	5,249,668	-
Travelling and entertainment	681,410	-
Vehicle running	392,263	-
Depreciation	506,250	-
Handling, freight and transportation	7,710,000	-
Stock written off - note 18.2	502,012,477	-
Reversal of provision for slow moving, obsolete and damaged stock in trade	(2,111,796)	-
Others	44,524	-
	<u>1,007,116,241</u>	<u>-</u>
Stock of work-in-process transferred - note 1.1	6,794,629	-
Closing stock of work-in-process	(16,207,828)	-
	<u>997,703,042</u>	<u>-</u>
Stock of finished goods transferred - note 1.1	543,289,395	-
Purchase of finished goods	2,835,564,249	-
	<u>4,376,556,686</u>	<u>-</u>
Closing stock of finished goods	(509,488,194)	-
	<u><u>3,867,068,492</u></u>	<u><u>-</u></u>

**18.1** Salaries, wages and other benefits include Rs. 275,034 (2015: Rs. Nil) and Rs. 97,281 (2015: Rs. Nil) in respect of defined benefit plans and contributory provident fund respectively.

**18.2** A fire incident occurred on June 24, 2016 at one of the Company's third party warehouses located at main Hawksbay Road, Karachi. The Company's management has ascertained that stocks amounting to Rs. 502.01 million were destroyed at the warehouse and the same has been written off in these financial statements.

Subsequently, the management filed a claim with the Insurance Company with regards to the burnt stock. The Insurance Company pursuant to filing the claim, has acknowledged the claim and the Company has received the insurance claim amounting to Rs. 506.25 million.



		For the period from March 31, 2015 to December 31, 2015 Rupees
	2016 Rupees	
<b>19. SELLING, MARKETING AND DISTRIBUTION EXPENSES</b>		
Salaries, wages and other benefits - note 19.1	101,939,110	-
Sales promotion	325,558,350	-
Advertising	364,996,893	-
Handling, freight and transportation	82,804,164	-
Travelling and entertainment	30,133,270	-
Depreciation	8,096,486	-
Vehicle running	4,154,705	-
Provision for doubtful debts	152,035	-
Repairs and maintenance	2,333,775	-
Insurance	2,034,303	-
Printing and stationery	50,361	-
Security expenses	1,431,816	-
Shared services cost - note 20.2	58,631,400	-
Other expenses	1,887,561	-
	<u>984,204,229</u>	<u>-</u>

**19.1** Salaries, wages and other benefits include Rs. 2,347,542 (2015: Rs. Nil) and Rs. 2,631,224 (2015: Rs. Nil) in respect of defined benefit plan and contributory provident fund respectively.

		For the period from March 31, 2015 to December 31, 2015 Rupees
	2016 Rupees	
<b>20. ADMINISTRATIVE EXPENSES</b>		
Salaries, wages and other benefits - note 20.1	58,902,685	-
Depreciation	1,545,249	-
Communication	30,000	-
Legal and professional charges	9,652,233	2,700
Rent, rates and taxes	4,241,680	-
Travelling and entertainment	3,358,306	-
Repairs and maintenance	104,880	-
Auditors' remuneration - note 20.2	4,831,433	250,000
Vehicle running	2,163,003	-
Publication and subscriptions	3,965,582	-
Insurance	545,665	-
Printing and stationery	297,300	-
Management fees - note 1.2	9,000,000	-
Shared services cost - note 20.2	31,978,494	-
Others	1,335,837	-
	<u>131,952,347</u>	<u>252,700</u>

**20.1** Salaries, wages and other benefits include Rs. 2,672,844 (2015: Rs. Nil) and Rs. 2,015,806 (2015: Rs. Nil) in respect of defined benefit plan and contributory provident fund respectively.

**20.2** These represent cost reimbursements to GSK Pakistan against cost of various functions / services provided to the Company due under cost sharing agreement.



		For the period from March 31, 2015 to December 31, 2015
	2016 Rupees	Rupees
<b>20.2 Auditors' remuneration</b>		
Audit fee	2,630,250	250,000
Special certifications and others	1,760,735	-
Out-of-pocket expenses	440,448	-
	<u>4,831,433</u>	<u>250,000</u>
<b>21. OTHER OPERATING EXPENSES</b>		
Workers' Profits Participation Fund	46,473,000	-
Workers' Welfare Fund	18,683,000	-
	<u>65,156,000</u>	<u>-</u>
<b>22. OTHER INCOME</b>		
<b>Income from financial asset</b>		
Income on deposit account	21,982,068	-
Interest income on loan to GlaxoSmithKline OTC (Private) Limited	1,689,041	-
<b>Income from non-financial assets</b>		
Gain on disposal of operating assets	278,683	-
<b>Others</b>		
Insurance claim recovery - note 18.2	506,245,038	-
	<u>530,194,830</u>	<u>-</u>
<b>23. FINANCIAL CHARGES</b>		
Exchange loss - net	1,223,405	-
Bank charges	331,204	-
	<u>1,554,609</u>	<u>-</u>
<b>24. TAXATION</b>		
Current	313,606,236	-
Deferred	(3,007,873)	-
	<u>310,598,363</u>	<u>-</u>
<b>24.1 Relationship between tax expense and accounting profit</b>		
Profit / (loss) before taxation	<u>856,063,755</u>	<u>(252,700)</u>
Applicable tax rate	<u>31%</u>	<u>32%</u>
Tax calculated at applicable tax rate	265,379,764	-
Impact of taxability at different rate and Final Tax Regime	49,272,841	-
Effect of tax credits	(8,993,385)	-
Effect of change in tax rate	1,713,187	-
Tax effect of other than temporary differences	3,225,956	-
	<u>310,598,363</u>	<u>-</u>



	2016 Rupees	2015 Rupees
<b>25. EARNINGS PER SHARE</b>		
Profit / (loss) after taxation	<u>545,465,392</u>	<u>(252,700)</u>
Weighted average number of outstanding shares	<u>71,727,780</u>	<u>3</u>
Earnings / (loss) per share - basic	<b>Rs. 7.60</b>	<b>Rs. (84,233.33)</b>
<b>25.1</b>	A diluted earnings per share has not been presented as the Company did not have any convertible instruments in issue which would have any effect on the earnings per share if the option to convert is exercised.	
	2016 Rupees	2015 Rupees
<b>26. CASH GENERATED FROM OPERATIONS</b>		
Profit / (loss) before taxation	856,063,755	(252,700)
<b>Add / (less): Adjustments for non-cash charges and other items</b>		
Depreciation	10,147,985	-
Gain on disposal of operating assets	(278,683)	-
Interest income	(23,671,109)	-
Provision for slow moving, obsolete and damaged stock-in-trade net of stock written off	(2,111,796)	-
Provision for doubtful debts	152,035	-
Provision for staff retirement benefits	5,202,470	-
	<u>(10,559,098)</u>	-
Profit before working capital changes	845,504,657	(252,700)
<b>Effect on cash flow due to working capital changes</b>		
(Increase) / decrease in current assets		
Stock-in-trade	101,242,732	-
Trade debts	(82,875,338)	-
Loans and advances	(20,311,938)	-
Refunds due from government	(17,242,440)	-
Other receivables	(104,709,514)	-
	<u>(123,896,498)</u>	-
Increase in current liabilities		
Trade and other payables	554,879,327	255,760
	<u>430,982,829</u>	<u>255,760</u>
	<u>1,276,487,486</u>	<u>3,060</u>
<b>27. CASH AND CASH EQUIVALENTS</b>		
Cash and bank balances - note 11	<u>670,342,359</u>	<u>3,090</u>

## 28. REMUNERATION OF CHIEF EXECUTIVE AND DIRECTORS

The amounts charged in these financial statements for remuneration of the Chief Executive and Directors are as follows:

	Chief Executive		Director	
	2016	2015	2016	2015
	Rupees			
Managerial remuneration	8,262,080	-	3,114,039	-
Bonus - note 28.1	12,819,627	-	3,044,785	-
Retirement benefits*	1,578,697	-	577,826	-
House rent	3,682,809	-	1,347,960	-
Utilities	818,406	-	299,551	-
Medical expenses	81,601	-	35,747	-
Others	421,317	-	555,547	-
	<u>27,664,537</u>	<u>-</u>	<u>8,975,455</u>	<u>-</u>
Number of person	<u>1</u>	<u>1</u>	<u>1</u>	<u>1</u>

\* Retirement benefits represent amount contributed towards various retirement benefit plans.

**28.1** Bonus includes share based payments as Share Appreciation Rights (SARs) given to the Chief Executive and Executive Director amounting to Rs. 7.04 million (2015: Rs. Nil). These are granted every year and are payable upon completion of three years of qualifying period of service. These are linked with the share value of ultimate parent company, GlaxoSmithKline plc, UK. Accruals made for bonus during the year are actualised subsequent to the year end when performance evaluations are finalised; and comparative figures are adjusted accordingly.

Chief Executive and Executive Director are also provided with free use of Company maintained cars in accordance with the Company policy.

## 29. TRANSACTIONS WITH RELATED PARTIES

Relationship	Nature of transactions	2016 Rupees	2015 Rupees
Associated companies:			
	a. Purchase of goods	2,835,564,249	-
	b. Management fees charged by GSK Pakistan	9,000,000	-
	c. Expenses cross charged by GSK Pakistan	90,609,894	-
	d. Loan to GlaxoSmithKline OTC (Private) Limited	1,000,000,000	-
	e. Interest income on loan to GlaxoSmithKline OTC (Private) Limited	1,689,041	-
Staff retirement funds:			
	a. Expense charged for retirement benefit plans	9,902,470	-
	b. Payments to retirement benefit plans	9,742,201	-
Key management personnel:			
	a. Salaries and other employee benefits	36,712,780	-
	b. Post employment benefits	4,024,147	-

**29.1** Balances of related parties as at December 31, 2016 are included in the respective notes to the financial statements. These are settled in the ordinary course of business. The receivables and payables are mainly unsecured in nature and bear no interest.

### 30. RUNNING FINANCE UNDER MARK-UP ARRANGEMENTS

The facilities for opening letters of credit as at December 31, 2016 amounted to Rs. 502.08 million (2015: Rs. Nil) which were unutilised at the year end.

The facilities for standby letters of credit and guarantees as at December 31, 2016 amounted to Rs. 95 million (2015: Rs. Nil) which were unutilised at the year end.

### 31. FINANCIAL INSTRUMENTS AND RELATED DISCLOSURES

#### 31.1 Financial assets and liabilities

All the financial assets of the Company, except treasury bills classified as held to maturity, are categorised as loans and receivables and all the financial liabilities are categorised as financial liabilities measured at amortised cost. The carrying values of all financial assets and liabilities approximate their fair values.

	Interest bearing			Non-interest bearing			Total
	Maturity up to one year	Maturity after one year	Total	Maturity up to one year	Maturity after one year	Total	
	← Rupees →						
<b>Financial assets</b>							
Loans to employees	-	-	-	1,734,575	638,747	2,373,322	2,373,322
Trade debts	-	-	-	315,941,587	-	315,941,587	315,941,587
Interest accrued	-	-	-	1,902,192	-	1,902,192	1,902,192
Loan to GlaxoSmithKline OTC (Private) Limited	1,000,000,000	-	1,000,000,000	-	-	-	1,000,000,000
Other receivables	-	-	-	120,374,628	-	120,374,628	120,374,628
Cash and bank balances	500,000,000	-	500,000,000	170,342,359	-	170,342,359	670,342,359
<b>December 31, 2016</b>	<b>1,500,000,000</b>	<b>-</b>	<b>1,500,000,000</b>	<b>610,295,341</b>	<b>638,747</b>	<b>610,934,088</b>	<b>2,110,934,088</b>
December 31, 2015	-	-	-	-	-	-	-
<b>Financial liabilities</b>							
Trade and other payables	-	-	-	1,123,600,213	-	1,123,600,213	1,123,600,213
<b>December 31, 2016</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>1,123,600,213</b>	<b>-</b>	<b>1,123,600,213</b>	<b>1,123,600,213</b>
December 31, 2015	-	-	-	-	-	-	-
<b>On balance sheet gap</b>							
<b>December 31, 2016</b>	<b>1,500,000,000</b>	<b>-</b>	<b>1,500,000,000</b>	<b>(513,304,872)</b>	<b>638,747</b>	<b>(512,666,125)</b>	<b>987,333,875</b>
December 31, 2015	-	-	-	-	-	-	-

The effective mark-up rates for the financial assets and liabilities are mentioned in respective notes to the financial statements.

#### 31.2 Financial Risk Management

##### (a) Market risk

##### (i) Interest rate risk

Interest rate risk is the risk that the value of a financial instrument will fluctuate due to changes in the market interest rates. As at December 31, 2016 the Company does not have any borrowings. Further, the interest bearing financial assets of Rs. 500 million (2015: Rs. Nil) are on fixed interest rates, hence management believes that the Company is not exposed to interest rate changes.

**(ii) Currency risk**

Foreign currency risk arises mainly where receivables and payables exist in foreign currency due to transactions with foreign undertakings. Net payables exposed to foreign currency risk as at December 31, 2016 amount to Rs. 151.62 million (2015: Rs. Nil). The liability is mainly denominated in US Dollars. At December 31, 2016, if the Pakistan Rupee had weakened / strengthened by 5% against the US Dollar with all other variables held constant, post-tax profit for the year would have been lower / higher by Rs. 7.58 million (2015: Rs. Nil).

**(b) Credit risk**

Credit risk represents the accounting loss that would be recognised at the reporting date if counterparts failed to perform as contracted. The analysis of maximum exposure to credit risk resulting from each class of financial assets is as follows:

	<b>2016</b>	2015
	<b>Rupees</b>	Rupees
Trade debts	<b>315,941,587</b>	-
Loans to employees, interest accrued and other receivables	<b>124,650,142</b>	-
Bank balances	<b>670,342,359</b>	-
	<b><u>1,110,934,088</u></b>	<u>-</u>

Trade debts of the Company are not exposed to significant credit risk as the Company trades with credit worthy third parties. Trade debts of Rs. 20.28 million (2015: Rs. Nil) are past due of which Rs. 6.77 million (2015: Rs. Nil) have been impaired.

Loans to employees are secured against their retirement benefits.

Bank balances represent low credit risk as these are placed with banks having good credit rating assigned by credit rating agencies.

**(c) Liquidity risk**

Liquidity risk reflects the Company's inability in raising funds to meet commitments. The Company manages liquidity risk by maintaining sufficient cash and balances with banks in deposit accounts and arranging financing through banking facilities and managing timing of payments to associated undertakings.

**32. PROVIDENT FUND RELATED DISCLOSURES**

The following information is based on un-audited financial statements of the Provident Funds (the Funds):

	<b>2016</b>	2015
	<b>Rupees</b>	Rupees
Size of the Funds - Total assets	59,394,744	-
Fair value of investments	59,394,744	-
Percentage of investments made	100%	-

*mm*

- 32.1 The cost of the above investments amounted to Rs. 59.39 million (2015: Rs. Nil).
- 32.2 The investments comprises entirely of bank deposits.
- 32.3 The investments out of provident funds have been made in accordance with the provisions of Section 227 of the Companies Ordinance, 1984 and the rules formulated for this purpose.

	2016	2015
<b>33. NUMBER OF EMPLOYEES</b>		
Number of employees including contractual employees at the end of year / period	<u>55</u>	<u>-</u>
Average number of employees including contractual employees during the year / period	<u>58</u>	<u>-</u>

**34. CAPITAL RISK MANAGEMENT**

The Company's objectives when managing capital are to safeguard the Company's ability to continue as a going concern so that it can continue to provide adequate returns for shareholders and benefits for other stakeholders and to maintain an optimal return on capital employed. The current capital structure of the Company is equity based with no financing through borrowings.

**35. DATE OF AUTHORISATION FOR ISSUE**

These financial statements were approved and authorised for issue by the Board of Directors of the Company on 25 JAN 2017

*MT*

  
Chief Executive

  
Director